A Randomised, Double-blind, Multi-centre Study to Evaluate the Efficacy and Safety of Inhaled Fluticasone Furoate in the Treatment of Persistent Asthma in Adults and Adolescents Currently Receiving Mid to High Strength Inhaled Corticosteroids.
Overview
- Phase
- Phase 3
- Intervention
- albuterol/salbutamol
- Conditions
- Asthma
- Sponsor
- GlaxoSmithKline
- Enrollment
- 238
- Locations
- 1
- Primary Endpoint
- Change From Baseline in Clinic Visit Evening (Pre-bronchodilator and Pre-dose) Forced Expiratory Volume in One Second (FEV1) at the End of the 24-week Treatment Period
- Status
- Completed
- Last Updated
- 9 years ago
Overview
Brief Summary
A randomised, double-blind, multi-centre study to evaluate the efficacy and safety of two doses of inhaled fluticasone furoate in the treatment of persistent asthma in adults and adolescents currently receiving mid to high strength inhaled corticosteroids.
Detailed Description
This will be a multi-centre, randomised, double-blind, parallel-group study. Subjects meeting all the inclusion criteria and none of the exclusion criteria during Visit 1 (screening visit) will enter a four week Run-In period during which they will remain on their baseline ICS medication. In addition, all subjects will be provided with albuterol/salbutamol for relief of asthma symptoms. Subjects failing screening will not be eligible for re-screening. During the Run-In and double-blind treatment periods subjects will maintain an electronic daily diary to record morning and evening Peak Expiratory Flow (PEF), asthma symptom score and rescue albuterol/salbutamol use. Subjects will receive a contact (Phone Contact 1/optional office visit (1b)) during Run-In to reinforce compliance with Run-In medication and diary monitoring. Those subjects who meet the eligibility criteria at the end of the Run-In period will be stratified in an approximately 1:1 ratio according to their baseline FEV1 as a percentage of predicted normal - one stratum for those with FEV1 percent predicted ≥40% to ≤65% and one for those with FEV1 percent predicted \>65% to ≤90%. Once stratified, subjects will be randomised to one of the following treatments and enter into a 24 week double-blind treatment period:1) Fluticasone furoate 100mcg once daily in the evening or 2) Fluticasone furoate 200mcg once daily in the evening. Subjects will then attend 6 on-treatment visits at Visits 3, 4, 5, 6, 7 and 8 (Weeks 2, 4, 8, 12, 18 and 24 respectively). All visits including Visit 1 must be conducted in the evening between 5 PM and 11 PM. Subjects will receive treatment for 24 weeks. Twenty four hour urinary cortisol assessments will be collected at the end of Run-In (Visit 2) and at end of treatment (Visit 8) visits. A follow-up contact will be performed 1-week after completing study medication (Visit 9). Subjects will participate in the study for up to a maximum of 29 weeks (including screening, treatment and follow-up contact). In addition, partially used NDPIs will be collected in a subset of subjects. For subjects who have consented for pharmacogenetics, a blood sample will also be taken for pharmacogenetic analysis.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Signed informed consent
- •Outpatient at least 12 years of age with diagnosis of asthma at least 12 weeks prior to first visit
- •Both genders; females of child bearing potential must be willing to use appropriate contraception
- •Pre-bronchodilator FEV1 of 40-90% predicted
- •Reversibility FEV1 of at least 12% and 200mLs
- •Current asthma therapy that includes inhaled corticosteroid for at least 4 weeks prior to first visit
Exclusion Criteria
- •History of life threatening asthma
- •Respiratory infection or candidiasis
- •Asthma exacerbation requiring OCS within last 4 weeks or overnight hospital stay within the last 3 months
- •Concurrent respiratory disease or other disease that would confound study participation of affect subject safety
- •Allergies to study drugs, study drug excipients, medications related to study drugs
- •Taking another investigational medication or medication prohibited for use during the study
- •Previous treatment with FF or FF/VI in a phase II or III study
- •Night shift workers
- •Children in care
Arms & Interventions
FF 100mcg once daily
Inhaled corticosteroid (ICS)
Intervention: albuterol/salbutamol
FF 200mcg once daily
Inhaled corticosteroid
Intervention: fluticasone furoate
FF 200mcg once daily
Inhaled corticosteroid
Intervention: albuterol/salbutamol
FF 100mcg once daily
Inhaled corticosteroid (ICS)
Intervention: fluticasone furoate
Outcomes
Primary Outcomes
Change From Baseline in Clinic Visit Evening (Pre-bronchodilator and Pre-dose) Forced Expiratory Volume in One Second (FEV1) at the End of the 24-week Treatment Period
Time Frame: Baseline and Week 24
FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Evening clinic visit FEV1 is defined as the clinic visit (pre-bronchodilator and pre-dose) FEV1 measurement taken at the Week 24 clinic visit. Pre-dose and pre-rescue albuterol/salbutamol trough FEV1 were measured electronically by spirometry in the evening at the Baseline through Week 24 clinic visits. The highest of 3 technically acceptable measurements was recorded. Baseline was the pre-dose value obtained at Visit 2. Change from Baseline was calculated as the Week 24 value minus the Baseline value. Analysis was performed using analysis of covariance (ANCOVA) with covariates of Baseline, region, sex, age, and treatment. The last observation carried forward (LOCF) method was used to impute missing data, in which the last non-missing, pre-dose, post-Baseline on-treatment measurement at scheduled clinic visits was used to impute the missing value.
Secondary Outcomes
- Change From Baseline in Daily Morning (AM) PEF Averaged Over the 24-week Treatment Period(From Baseline up to Week 24)
- Change From Baseline in the Percentage of Rescue-free 24-hour (hr) Periods Over the 24-week Treatment Period(From Baseline up to Week 24)
- Change From Baseline in Daily Evening (PM) Peak Expiratory Flow (PEF) Averaged Over the 24-week Treatment Period(From Baseline up to Week 24)
- Change From Baseline in the Percentage of Symptom-free 24-hour (hr) Periods Over the 24-week Treatment Period(From Baseline up to Week 24)